Regeneron Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 (€50,394 Mil) to Dec. 2025 (€69,710 Mil) and
increased
from Dec. 2025 (€69,710 Mil) to Mar. 2026 (€70,151 Mil).
Regeneron Pharmaceuticals's annual market cap
declined
from Dec. 2023 (€86,495 Mil) to Dec. 2024 (€74,276 Mil) and
declined
from Dec. 2024 (€74,276 Mil) to Dec. 2025 (€69,710 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Regeneron Pharmaceuticals's Enterprise Value for Today is €52,202 Mil.
Regeneron Pharmaceuticals (STU:RGO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Regeneron Pharmaceuticals Market Cap Related Terms
Regeneron Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (STU:RGO) has a Market Cap of €57,512 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regeneron Pharmaceuticals and its competitors. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #2 out of 1427 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Regeneron Pharmaceuticals' Market Cap too high?
Regeneron Pharmaceuticals' current Market Cap is €57,512 Mil. Based on the distribution chart, Regeneron Pharmaceuticals ranks #2 out of 1427 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Market Cap compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #2 out of 1427 companies for Market Cap. This places Regeneron Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regeneron Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regeneron Pharmaceuticals's current Market Cap is €57,512 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €792.90, compared to a current price of €571.70 — trading 27.9% below its estimated fair value. The current Market Cap is €57,512 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Market Cap is €57,512 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €571.70 is trading 27.9% below its estimated GF Value™ of €792.90.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for STU:RGO:
Market Cap: €57,512 Mil
GF Value™: €792.90 vs. price of €571.70 (27.9% below fair value)
No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
78GF Score
Get the complete analysis for STU:RGO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RGO has been successfully added to your 
